These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 39177933)

  • 1. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.
    Brufsky A; Kwan ML; Sandin R; Stergiopoulos S; Karanth S; Cha-Silva AS; Makari D; Goyal RK
    Breast Cancer Res Treat; 2024 Nov; 208(2):223-235. PubMed ID: 39177933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities in receipt of 1-
    Pilehvari A; Kimmick G; You W; Bonilla G; Anderson R
    Breast Cancer Res; 2024 Oct; 26(1):144. PubMed ID: 39425174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials.
    Li H; Wu Y; Zou H; Koner S; Plichta JK; Tolaney SM; Zhang J; He YW; Wei Q; Tang L; Zhang H; Zhang B; Guo Y; Chen X; Li K; Lian L; Ma F; Luo S
    EBioMedicine; 2024 Jul; 105():105186. PubMed ID: 38861871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.
    Kimmick G; Pilehvari A; You W; Bonilla G; Anderson R
    Breast Cancer Res Treat; 2024 Nov; 208(2):263-273. PubMed ID: 38922546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
    Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S
    Clin Transl Oncol; 2024 Jul; 26(7):1748-1758. PubMed ID: 38519708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.
    Goyal RK; Chen H; Abughosh SM; Holmes HM; Candrilli SD; Johnson ML
    Cancer; 2023 Apr; 129(7):1051-1063. PubMed ID: 36760031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
    Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
    BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
    Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM
    J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
    Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U
    Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a systematic review and meta-analysis.
    Masurkar PP; Prajapati P; Canedo J; Goswami S; Earl S; Bhattacharya K
    Curr Med Res Opin; 2024 Oct; 40(10):1753-1767. PubMed ID: 39305463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.
    Harbeck N; Bartlett M; Spurden D; Hooper B; Zhan L; Rosta E; Cameron C; Mitra D; Zhou A
    Future Oncol; 2021 Jun; 17(16):2107-2122. PubMed ID: 33663223
    [No Abstract]   [Full Text] [Related]  

  • 15. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Alvarez A; Bernal AM; Anampa J
    Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
    Meegdes M; Geurts SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Teeuwen NJA; de Boer M; Tjan-Heijnen VCG
    Int J Cancer; 2022 Jan; 150(1):124-131. PubMed ID: 34460112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
    Cetin B; Wabl CA; Gumusay O
    Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
    Wu Y; Mo H; Xu H; Wang Y; Wang J; Ma F; Xu B
    Thorac Cancer; 2024 Apr; 15(12):965-973. PubMed ID: 38480513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Önder T; Ateş Ö; Öner İ; Karaçin C
    Clin Breast Cancer; 2024 Aug; 24(6):519-526. PubMed ID: 38879437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.